Neumora Therapeutics Inc (NMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||
| Net Income | -243,787 | -235,925 | -130,904 |
| Depreciation Amortization | -5,088 | -3,073 | -114 |
| Accounts payable and accrued liabilities | 2,873 | -581 | -1,246 |
| Other Working Capital | 22,636 | -8,899 | -6,948 |
| Other Operating Activity | 40,430 | 85,200 | 24,316 |
| Operating Cash Flow | $-182,936 | $-163,278 | $-114,896 |
| Cash Flows From Investing Activities | |||
| PPE Investments | N/A | -117 | -511 |
| Purchase Of Investment | -312,223 | -109,072 | -226,369 |
| Sale Of Investment | 242,441 | 178,166 | 71,867 |
| Other Investing Activity | -775 | -4,590 | -13,000 |
| Investing Cash Flow | $-70,557 | $64,387 | $-168,013 |
| Cash Flows From Financing Activities | |||
| Common Stock Issued | 21,176 | 236,231 | 4,271 |
| Common Stock Repurchased | N/A | -491 | N/A |
| Other Financing Activity | 427 | -3,804 | 111,472 |
| Financing Cash Flow | $21,603 | $231,936 | $115,743 |
| Beginning Cash Position | 375,251 | 242,206 | 409,372 |
| End Cash Position | 143,361 | 375,251 | 242,206 |
| Net Cash Flow | $-231,890 | $133,045 | $-167,166 |
| Free Cash Flow | |||
| Operating Cash Flow | -182,936 | -163,278 | -114,896 |
| Capital Expenditure | N/A | -117 | -511 |
| Free Cash Flow | -182,936 | -163,395 | -115,407 |